Invention Grant
- Patent Title: Pharmaceutical formulation containing gelling agent
-
Application No.: US16229188Application Date: 2018-12-21
-
Publication No.: US10537526B2Publication Date: 2020-01-21
- Inventor: Curtis Wright , Benjamin Oshlack , Christopher Breder
- Applicant: Purdue Pharma L.P. , The P.F. Laboratories, Inc. , Purdue Pharmaceuticals L.P.
- Applicant Address: US CT Stamford
- Assignee: Purdue Pharma L.P.
- Current Assignee: Purdue Pharma L.P.
- Current Assignee Address: US CT Stamford
- Agency: Davidson, Davidson & Kappel, LLC
- Main IPC: A61K9/20
- IPC: A61K9/20 ; A61K9/00 ; A61K31/439 ; A61K31/485 ; A61K47/38 ; A61K47/36 ; A61K47/10 ; A61K45/06 ; A61K31/167 ; A61K31/192 ; A61K9/16 ; A61K47/26 ; A61K31/48 ; A61K9/48 ; A61K47/08 ; A61K9/50 ; A61K47/32 ; A61K9/08 ; A61K9/28 ; A61K47/12 ; A61K47/34 ; A61K9/06 ; A61K31/4458 ; A61K31/137 ; A61K47/14 ; A61K9/70 ; A61J3/10 ; A61K47/02 ; A61K9/19 ; A61K8/73 ; A61K47/20

Abstract:
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Public/Granted literature
- US20190117580A1 Pharmaceutical Formulation Containing Gelling Agent Public/Granted day:2019-04-25
Information query